Bioversys Ag

Vincent Trebosc

Glenn E Dale

Marc Gitzinger

Sergio Lociuro

Nicolas Willand

Christian Kemmer

Marilyne Bourotte

Olivier Defert

Kevin Antraygues

Bruna Gioia

Mathieu Maingot

The invention provides antibiotic combination therapies for treating aninfection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

Antibiotic combination therapies

The invention provides systems and methods for increased clinical efficacy of rifabutin against. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin intocells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection ofin the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or C. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cis that greater than about 2 mg/L and optionally less than about 50 mg/L.

Rifabutin treatment methods, uses, and compositions

Growing community of inventors

Rixheim, France

Vincent Trebosc